VTVT

At a glance

vTv Therapeutics Inc. (VTVT) is listed on NASDAQ and classified in Biotechnology, part of the Healthcare sector. It is headquartered in High Point, United States and has 26 employees. The company is worth $104.94M. Revenue was $0 in fiscal 2025, down 100.0% from the year before. It reported a net loss of $26.97M. The share price is 39.7% below its 52-week high of $44.00. 5 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Israel Englander (Millennium Management), at $10.16M. In that quarter, 1 of them opened or added to the position. No open-market insider trades in it were filed over the last 30 days.

Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.

Key metrics

Market cap

$104.94M

P/E

—

Forward P/E

—

P/B

4.2x

Dividend yield

0.00%

Payout

—

EPS

-$0.72

ROE

-15.80%

Profit margin

-12.91%

Revenue growth

—

Beta

0.21

52-week high

$44.00

52-week low

$19.50

History

Year by year, from the annual reports; dividends from the payments themselves.

Investors holding this

Major managers that reported this stock in their latest 13F.

• IE
  Israel Englander+ Added

  Millennium Management · Q2 2026
  $10.16M

  269.87K shares · 0.0% of portfolio
• RT
  Renaissance TechnologiesHeld

  Renaissance Technologies · Q2 2026
  $657.14K

  17.45K shares · 0.0% of portfolio
• TS
  Two SigmaHeld

  Two Sigma Investments · Q2 2026
  $432.45K

  11.49K shares · 0.0% of portfolio

Indicators, year by year

The last 4 closed years, each at that year’s closing price and reported numbers.

Others in the same sector

Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.

About the company